Genuine OEM printer cartridges enter the recycle stream to be resold at discounted prices Planet Green Recycle receives thousands of new, previously owned genuine OEM ink and toner cartridges through their recycling program Planet Green Recycle Maintains More Than 3,000 New, Pre-Owned OEM Ink and Toner Products From Major Printer Manufacturers The greenest cartridge is often the one that already exists,” — Neil Levi CHATSWORTH, CA, UNITED STATES, June 24, 2026 / EINPresswire.com/ -- The...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Eric Sherman
Ecommerce Growth Creates New Opportunity for Online Retailers to Expand Into Ink and Toner Sales
Ecommerce growth is creating new opportunities for retailers to enter the multibillion-dollar ink and toner market through drop shipping and private labeling.
U.S. OEM Resellers Turn to Domestic Remanufactured Ink Suppliers to Improve Margins and Fill SKU Gaps
Planet Green offers more than 800 inkjet SKUs, helping resellers fill product gaps, improve margins and provide cost-effective alternatives to OEM cartridges. Used OEM cores are remanufactured back into a new high-quality ink cartridge As costs rise and margins tighten, dealers are adopting U.S. remanufactured ink cartridges to fill SKU gaps and improve profitability.
Schools, Nonprofits Raise Needed Funds Through Ink Cartridge Recycling Program
Planet Green Awards Oversized Check to school for ink cartridge recycling Rio Hondo Academy toured Planet Green to learn more about recycling Estimated 375 million cartridges enter U.S. landfills a year when they can be recycled. Thousands of Organizations Participate in Recycling Effort That Supports Fundraising and Reduces Landfill Waste.
Decline of U.S. Printer Cartridge Remanufacturing Sector Draws Industry Attention
One of the last U.S. printer cartridge remanufacturers. Printer cartridge remanufacturing facility U.S. cartridge remanufacturing has declined as imports gained market share, shifting production overseas and raising sustainability concerns.
Uncommon Neuro-Ophthalmologic Findings in Pediatric Lyme Disease
Specialty Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional.
Optimal post-treatment surveillance strategy for human papillomavirus-positive oropharyngeal cancer
|
By Caineng Cao, Eric Sherman, Nadeem Riaz, Sean McBride, Yao Yu, Achraf A. Shamseddine, Winston Wong Verified, Lara Dunn, Nancy Lee
|
Cell Reports Medicine
Verified
Keywords surveillance cost-effectiveness analysis oropharyngeal cancer human papilloma virus recurrence Introduction Post-treatment surveillance is critically important for enhancing survival outcomes, as it facilitates the early detection of potentially salvageable cancer recurrences. For human papillomavirus (HPV)-positive oropharyngeal cancer, there is currently no consensus on the optimal post-treatment surveillance schedule and regimen.
A Screening Strategy to Mitigate Vision Impairment by Engaging Adults Who Underuse Eye Care Services
A Screening Strategy to Mitigate Vision Impairment by Engaging Adults Who Underuse Eye Care Services Key Points Question Were adults at high risk of eye disease using eye care services before participating in the Screening and Intervention for Glaucoma and Eye Health Through Telemedicine Program? Findings In a cross-sectional study including 1171 participants in an eye care program, 55% had not had an eye examination in 2 or more years.
Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma
Authors retain all rights in any data supplements associated with their articles. The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned.
Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma
Data Supplement Authors retain all rights in any data supplements associated with their articles. The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned.
Rebuttal to comment on “Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer”
No abstract is available for this article. REFERENCES 1, , , et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019; 393(10166): 51-60. doi:10.1016/S0140-6736(18)32752-1/ATTACHMENT/FBACF3BD-CD7C-4549-B17A-2DC69AC7EC5B/MMC1.PDF 2, , , et al.
Biology, Diagnosis and Activity of Targeted Therapy in RET-Altered Cancers-A Tumor-Agnostic Review
1. Introduction Advances in molecular profiling and inclusive trial designs have transformed the therapeutic landscape for patients with cancer. Basket trials now enroll patients based primarily on the presence of oncogenic drivers, such as RET (rearranged during transfection) alterations, regardless of tumor type.
Collaboration in dissection at Mason County Eastern
Dispatchist News from around the globe in real time Client login Collaboration in dissection at Mason County Eastern CUSTER — Mason County Eastern seventh-graders in Noah Albrecht’s class worked with fourth-graders taught by Eric Sherman and Carol Rowe to dissect a cow eye on Monday.
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.
Intensity‐modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial
Original Article Paul B. Romesser MD, orcid.org/0000-0001-8268-2903 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Search for more papers by this author Eric J.
Eric J. Sherman, MD, on Agents for Treating RET Fusion-Positive Thyroid Cancer
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, who spotlighted agents that are currently used for the treatment of RET fusion–positive thyroid cancer.
Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer
Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J.
Eric J. Sherman, MD, on Immunotherapy Trends in Head and Neck Cancer
Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss immunotherapy trends in head and neck cancer.
Eric J. Sherman, MD, Discusses the Use of Adjuvant Capecitabine in Nasopharynx Cancer
Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J.
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Anaplastic thyroid cancer (ATC) is an aggressive follicular cell–derived malignancy associated with a historically poor prognosis and a 5-year survival rate of < 10%.1 Although ATC is rare and makes up only 2% of all thyroid cancers, it accounts for up to 50% of all thyroid cancer–related deaths.2 Until recently, available treatment options had limited efficacy, and the duration of response was generally short (2-5 months).3 CONTEXT Key Objective To further evaluate the role of lenvatinib in...
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
Article Tools ORIGINAL REPORTS Head and Neck Cancer Sean McBride, MD, MPH1; Eric Sherman, MD2,3; C.
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
Immune checkpoint blockade (ICB) therapy—specifically, antibodies targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1)—has significantly expanded the therapeutic armamentarium for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
The 3 Bs of cancer care amid the COVID‐19 pandemic crisis: “Be safe, be smart, be kind”-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer - Kang - 2020 - Cancer - Wiley Online Library
Abstract Because of the national emergency triggered by the coronavirus disease 2019 (COVID‐19) pandemic, government‐mandated public health directives have drastically changed not only social norms but also the practice of oncologic medicine. Timely head and neck cancer (HNC) treatment must be prioritized, even during emergencies.
Nasopharynx cancer: Induction or adjuvant? That is the question
Editorial Nancy Y. Lee MD Corresponding Author E-mail address: leen2@mskcc.org Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA Corresponding Author: Nancy Y. Lee, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021 (E-mail address: leen2@mskcc.org). Search for more papers by this author See referenced original article on pages 1‐3, 1‐15 this issue.
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer - Sherman - - Cancer - Wiley Online Library
Original Article Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer Eric J. Sherman MD Corresponding Author E-mail address: shermane@mskcc.org https://orcid.org/0000-0002-4960-4783 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medicine, New York, New York Corresponding author: Eric J.
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer
Original Article Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer Eric J. Sherman MD Corresponding Author E-mail address: shermane@mskcc.org https://orcid.org/0000-0002-4960-4783 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medicine, New York, New York Corresponding author: Eric J.
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma
Adenoid cystic carcinomas (ACCs) are malignant neoplasms that arise most commonly from major and minor salivary glands and less commonly from other sites. Recurrent or metastatic (R/M) ACC can have a variable course,1 and effective treatments are lacking.
Don't Get Possessed! Protection Against Adverse Possession
Eric Sherman, partner at Pryor Cashman As law students learn during their first-year course on property rights, there is a centuries-old common law doctrine called “adverse possession,” under which a person may actually acquire legal title to another person’s property by, among other things, openly occupying the property unchallenged over an extended period of time.
Therapy for Tough Guys
Couch is a series about psychotherapy. From the moment I heard Michael’s voice on my answering machine, I felt intrigued and intimidated. “Hey, Doc,” he said, though I am neither a doctor nor a character in a Bugs Bunny cartoon. “Word on the street is that you’re a damn good therapist. I might want to set up a meeting, but I’ve got a question. So give me a call and let’s talk.” I both bristled and chuckled at Michael’s moxie.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Eric
Contact Eric, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack